FLORENCE: A randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Michele Spina, Z. Nagy, J. M. Ribera, M. Federico, I. Aurer, K. Jordan, G. Borsaru, A. S. Pristupa, A. Bosi, S. Grosicki, N. L. Glushko, D. Ristic, J. Jakucs, P. Montesinos, J. Mayer, E. M. Rego, S. Baldini, S. Scartoni, A. Capriati, C. A. MaggiC. Simonelli

Research output: Contribution to journalArticle

Abstract

Background: Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk. We sought to determine whether febuxostat fixed dose achieves a better sUA control than allopurinol while preserving renal function in TLS prevention. Patients and methods: Patients with hematologic malignancies at intermediate to high TLS risk grade were randomized to receive febuxostat or allopurinol, starting 2 days before induction chemotherapy, for 7-9 days. Study treatment was blinded, whereas daily dose (low/standard/high containing allopurinol 200/300/600 mg, respectively, or fixed febuxostat 120 mg) depended on the investigator's choice. The co-primary end points, sUA area under curve (AUC sUA1-8) and serum creatinine change, were assessed from baseline to day 8 and analyzed through analysis of covariance with two-sided overall significance level of 5%. Secondary end points included treatment responder rate, laboratory and clinical TLS incidence and safety. Results: A total of 346 patients (82.1% intermediate TLS risk; 82.7% assigned to standard dose) were randomized. Mean AUC sUA1-8 was 514.0 ± 225.71 versus 708.0 ± 234.42 mgxh/dl (P <0.0001) in favor of febuxostat. Mean serum creatinine change was -0.83 ± 26.98% and -4.92 ± 16.70% for febuxostat and allopurinol, respectively (P = 0.0903). No differences among secondary efficacy end points were detected. Drug-related adverse events occurred in 6.4% of patients in both arms. Conclusion: In the largest adult trial carried out in TLS prevention, febuxostat achieved a significant superior sUA control with one fixed dose in comparison to allopurinol with comparable renal function preservation and safety profile. Clinical trial registration: NCT01724528.

Original languageEnglish
Article numbermdv317
Pages (from-to)2155-2161
Number of pages7
JournalAnnals of Oncology
Volume26
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Keywords

  • Allopurinol
  • Febuxostat
  • Hematologic malignancy
  • Kidney injury
  • Tumor lysis

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'FLORENCE: A randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk'. Together they form a unique fingerprint.

  • Cite this

    Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., Borsaru, G., Pristupa, A. S., Bosi, A., Grosicki, S., Glushko, N. L., Ristic, D., Jakucs, J., Montesinos, P., Mayer, J., Rego, E. M., Baldini, S., Scartoni, S., Capriati, A., ... Simonelli, C. (2015). FLORENCE: A randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26(10), 2155-2161. [mdv317]. https://doi.org/10.1093/annonc/mdv317